Nuklearmedizin - NuclearMedicine, Inhaltsverzeichnis

Nuklearmedizin 2015; 54(05): 211-216
DOI: 10.3413/Nukmed-0737-15-04

Original article

Schattauer GmbH

Significance of ¹⁸F-fluorocholine PET/CT positive pulmonary lesions in prostate cancer patients

Die Bedeutung ¹⁸F-Fluorcholin-PET/CT-positiver Lungenläsionen bei Patienten mit Prostatakarzinom

O. Rager

¹Department of Medical Imaging, Nuclear Medicine Division, Geneva University Hospitals, Geneva, Switzerland

,

A. Baskin

¹Department of Medical Imaging, Nuclear Medicine Division, Geneva University Hospitals, Geneva, Switzerland

²Department of Nuclear Medicine, Ankara Training and Research Hospital, Ankara, Turkey

,

G. Amzalag

¹Department of Medical Imaging, Nuclear Medicine Division, Geneva University Hospitals, Geneva, Switzerland

,

F. Buchegger

¹Department of Medical Imaging, Nuclear Medicine Division, Geneva University Hospitals, Geneva, Switzerland

,

R. Miralbell

³Department of Medical Imaging , Radiation-Oncology Division, Geneva University Hospitals, Geneva, Switzerland

,

O. Ratib

¹Department of Medical Imaging, Nuclear Medicine Division, Geneva University Hospitals, Geneva, Switzerland

,

T. Zilli

³Department of Medical Imaging , Radiation-Oncology Division, Geneva University Hospitals, Geneva, Switzerland

,

V. Garibotto

¹Department of Medical Imaging, Nuclear Medicine Division, Geneva University Hospitals, Geneva, Switzerland

› Institutsangaben

Summary

Aim: To assess the frequency and the significance of incidental pulmonary lesions with ¹⁸F-fluorocholine (¹⁸F-FCH) PET/CT in prostate cancer (PCa) patients. Patients, methods: 225 consecutive PCa patients referred for ¹⁸F-FCH PET/CT (median age 68 years) were retrospectively evaluated for the presence of lesions in the lungs: 173 referred for restaging and 52 for initial staging regarding their high risk of extra prostatic extension. The final diagnosis was based on histopathological or on clinical and radiological follow-up. Results: 13 patients had ¹⁸F-FCH positive pulmonary and 8 patients malignant lesions: 5 patients (38%) had a primary lung cancer (2 squamous cell carcinomas, 1 papillary adenocarcinoma, 1 typical pulmonary carcinoid, 1 bronchioloalveolar carcinoma) and 3 patients (23%) PCa metastases. Benign lesions were found in 5 subjects (38%). SUVmax and maximum diameter were neither significantly different in primary and metastatic tumors nor between malignant and benign lesions. Conclusions: Although our results suggest that incidental uptake in the lungs in PCa patients are nonspecific, their detection may have a significant impact on patient management knowing that more than 60% represent malignant diseas.

Zusammenfassung

Ziel: Untersuchung der Häufigkeit und Bedeutung von zufällig in der PET/CT mit ¹⁸F-Fluorcholin (¹⁸F-FCH) entdeckten Lungenrundherde bei Patienten mit Prostatakarzinom (PCa). Patienten, Methoden: 225 konsekutive ¹⁸F-FCH-PET/CT von PCa-Patienten (medianes Alter 68 Jahre) wurden retrospektiv auf das Vorhandensein von Lungenläsionen analysiert: Verdacht auf PCa-Rezidiv in 173 Fällen und initiales Staging bei hohem Risiko auf extra- prostatisches Wachstum in 52 Fällen. Die definitive Diagnose wurde histopathologisch oder aufgrund des klinischen und radiologischen Verlaufs erstellt. Ergebnisse: Bei 13 Patienten fanden sich ¹⁸F-FCH-positive Lungenbefunde, davon 8 mit maligner Histologie: 5 Patienten (38%) hatten primäre Lungentumore (2 Plattenepithelkarzinome, 1 papilläres Adenokarzinom, 1 typisches Lungenkarzinoid, 1 bronchioalveoläres Karzinom), bei 3 Patienten (23%) wurden PCa-Metastasen gefunden. Benigne Befunde wurden bei 5 Patienten (38%) erhoben. SUVmax und maximaler Durchmesser zeigten weder zwischen primären und metastatischen Lungenläsionen noch zwischen malignen und benignen Befunden signifikante Unterschiede. Schlussfolgerung: Obwohl unsere Resultate suggerieren, dass akzidentelle Lungenanreicherung von Fluorcholin bei PCa-Patienten unspezifisch ist, kann deren Nachweis einen signifikanten Einfluss auf das Management der Patienten haben unter Berücksichtigung der Tatsache, dass mehr als 60% der Befunde maligne sind.

Keywords

Keywords

¹⁸F-Fluorocholine - PET/CT - pulmonary metastases - prostate cancer - lung cancer

Schlüsselwörter

Schlüsselwörter

¹⁸F-Fluorcholin - PET/CT - Lungenmetastasen - Prostatakrebs - Lungenkrebs

References
1 Balogova S, Huchet V, Kerrou K. et al. Detection of bronchioloalveolar cancer by means of PET/CT and ¹⁸F-fluorocholine, and comparison with ¹⁸F-fluorodeoxyglucose. Nucl Med Commun 2010; 31: 389-397.
2 Calabria F, Chiaravalloti A, Tavolozza M. et al. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?. Nucl Med Commun 2013; 34: 733-740.
3 Chondrogiannis S, Marzola MC, Ferretti A. et al. Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40: 1356-1364.
4 DeGrado TR, Baldwin SW, Wang S. et al. Synthesis and evaluation of ¹⁸F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42: 1805-1814.
5 Field JK, Oudkerk M, Pedersen JH. et al. Prospects for population screening and diagnosis of lung cancer. Lancet 2013; 382: 732-741.
6 Ginsberg MS, Griff SK, Go BD. et al. Pulmonary nodules resected at video-assisted thoracoscopic surgery: etiology in 426 patients. Radiology 1999; 213: 277-282.
7 Hara T, Kosaka N, Kishi H. Development of ¹⁸F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002; 43: 187-199.
8 Hara T, Kosaka N, Suzuki T. et al. Uptake rates of ¹⁸F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest 2003; 124: 893-901.
9 Heinisch M, Dirisamer A, Loidl W. et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA< 5 ng/ml?. Mol Imaging and Biol 2006; 8: 43-48.
10 Jadvar H. Prostate cancer: PET with ¹⁸F-FDG, ¹⁸F- or 11C-acetate, and ¹⁸F- or 11C-choline. J Nucl Med 2011; 52: 81-89.
11 Kayser K, Donnwald D, Zink S. et al. Small pulmonary lesions--a challenge for thoracic surgery?. Sci World J 2001; 1: 906-913.
12 Khan N, Oriuchi N, Zhang H. et al. A comparative study of 11C-choline PET and [¹⁸F] fluorodeoxyglucose PET in the evaluation of lung cancer. Nucl Med Commun 2003; 24: 359-366.
13 Koo KC, Yoo H, Kim KH. et al. Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer. J Urol 2015; 193: 1239-1244.
14 Le C, van de Weijer EP, Pos FJ. et al. Active inflammation in ¹⁸F-methylcholine PET/CT. Eur J Nucl Med Mol Imaging 2010; 37: 654-655.
15 Levi F, Randimbison L, Rafael BM. et al. Second primary cancers in the Vaud and Neuchatel Cancer Registries. Eur J Cancer Prev 2015; 24: 150-154.
16 Libshitz HI, North LB. Pulmonary metastases. Radiol Clin North Am 1982; 20: 437-451.
17 Mamede M, Ceci F, Castellucci P. et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level<0.5 ng/mL. Clin Nucl Med 2013; 38: e342-e345.
18 Mertens K, Slaets D, Lambert B. et al. PET with ¹⁸F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging 2010; 37: 2188-2193.
19 Peng Z, Liu Q, Li M. et al. Comparison of 11C-choline PET/CT and enhanced CT in the evaluation of patients with pulmonary abnormalities and locoregional lymph node involvement in lung cancer. Clin Lung Cancer 2012; 13: 312-320.
20 Peng ZM, Liu Q, Liu QW. et al. The value of dual time point 11C-choline PET-CT in differentiating malignant from benign lesion of mediastinum. Zhonghua yi xue za zhi 2007; 87: 3317.
21 Picchio M, Briganti A, Fanti S. et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011; 59: 51-60.
22 Picchio M, Castellucci P. Clinical indications of C-choline PET/CT in prostate cancer patients with biochemical relapse. Theranostics 2012; 2: 313-317.
23 Picchio M, Messa C, Landoni C. et al. Value of [11C]choline-positron emission tomography for restaging prostate cancer: a comparison with [¹⁸F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337-1340.
24 Pieterman RM, Que TH, Elsinga PH. et al. Comparison of 11C-choline and ¹⁸F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med 2002; 43: 167-172.
25 Rietbergen DD, van der Hiel B, Vogel W. et al. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT. Nucl Med Commun 2011; 32: 1143-1147.
26 Roivainen A, Forsback S, Gronroos T. et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000; 27: 25-32.
27 Schillaci O, Calabria F, Tavolozza M. et al. ¹⁸F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 2010; 31: 39-45.
28 Schmid DT, John H, Zweifel R. et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235: 623-628.
29 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
30 Steiner C, Vees H, Zaidi H. et al. Three-phase ¹⁸F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence. Nuklearmedizin 2009; 48: 1-9.
31 Tian M, Zhang H, Oriuchi N. et al. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004; 31: 1064-1072.
32 Treglia G, Giovannini E, Di Franco D. et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012; 26: 451-461.
33 Tuncel M, Souvatzoglou M, Herrmann K. et al. [11C]choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008; 35: 689-695.
34 Vees H, Buchegger F, Albrecht S. et al. ¹⁸F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. Br J Urol International 2007; 99: 1415-1420.
35 Zeisel SH. Dietary choline: Biochemistry, physiology, and pharmacology. Ann Rev Nutr 1981; 1: 95-121.